Danyelza (naxitamab) is an antibody pharmaceutical. Naxitamab was first approved as Danyelza on 2020-11-25. It is used to treat neuroblastoma in the USA.
Trade Name |
Danyelza |
Common Name |
Naxitamab |
Indication |
neuroblastoma |
Drug Class |
Monoclonal antibodies: tumors |